BCRX BioCryst Pharmaceuticals Inc

On August 25, 2022, BioCryst Pharmaceuticals, Inc. (the “Company”) announced that it has entered into an amendment (the “Amendment”) to its contract dated September 1, 2018 with the Department of Health and Human Services (“HHS”) for the procurement of the Company’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection).  Pursuant to the Amendment, HHS exercised Option Period 4 under the contract to purchase an additional 10,000 doses of RAPIVAB during the period of September 1, 2022 through August 31, 2023 for a total price of approximately $6.9 million. The order is the final of five purchase options under the Company’s procurement contract for RAPIVAB.  This description of the Amendment is qualified in its entirety by reference to the full text of the Amendment furnished as Exhibit 10.1 to this Current Report on Form 8-K.

The Company has previously disclosed that it is commencing the close out of its September 2013 galidesivir contract with the National Institute of Allergy and Infectious Diseases within the HHS.  In addition, the Company’s other government funding for galidesivir is expected to expire later in 2022.  The Company has no plans to continue the galidesivir program without government funding.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including statements regarding sales of RAPIVAB and expectations regarding the Company’s galidesivir program.  These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results to be materially different from those expressed or implied by the forward-looking statements.  These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties.  Given these uncertainties, you should not place undue reliance on these forward-looking statements.  Some of the factors that could affect the forward-looking statements contained herein include:  the Company relies on third-party manufacturers to manufacture RAPIVAB in a timely manner and in accordance with applicable governmental regulations, and any failure of such third-party manufacturers to perform their obligations could impact the Company’s ability to supply RAPIVAB pursuant to its government procurement contract; the availability of government funding; government contracts contain certain terms and conditions that subject the Company to additional risks; and the ongoing COVID-19 pandemic, which could create challenges in all aspects of the Company’s business, including without limitation delays, stoppages, difficulties, and increased expenses with respect to the Company’s and its partners’ supply chains, negatively impact the Company’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening the other risks described herein or in the documents the Company files periodically with the Securities and Exchange Commission.  Please refer to the documents the Company files periodically with the Securities and Exchange Commission, specifically the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in the Company’s forward-looking statements.